Last Posted: Dec 12, 2019
- Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.
Ramaswami Uma et al. Atherosclerosis 2019 Nov 292178-187 - Genetic contribution to lipid target achievement with statin therapy: a prospective study.
Ruiz-Iruela Cristina et al. The pharmacogenomics journal 2019 Dec - Should we Consider Lipoprotein (a) in Cardiovascular Disease Risk Assessment in Patients with Familial Hypercholesterolaemia?
Anagnostis Panagiotis et al. Current pharmaceutical design 2018 24(31) 3665-3671 - Familial hypercholesterolaemia workshop for leveraging point-of-care testing and personalised medicine in association with the Lipid and Atherosclerosis Society of Southern Africa.
Marais A D et al. Cardiovascular journal of Africa 30(5) 297-304 - Many Adults with Familial Hypercholesterolemia Are Not Meeting Goal LDL-Cholesterol Level
RF Green et al, CDC Blog Post, November 15, 2019 - [PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated?Czech atherosclerosis society statement].
Soška Vladimír et al. Vnitrni lekarstvi 2016 Apr 62(4) 329-33 - [Recommendations for management of dyslipidemia in 2016 in Switzerland].
Aubert Carole E et al. Revue medicale suisse 2016 Mar 12(508) 430-4 - Patients with High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit from Alirocumab Treatment in the Odyssey Outcomes Trial.
Damask Amy et al. Circulation 2019 Nov - Why using genetic risk scores on embryos is wrong
E Birney blog, November 11, 2019 - Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).
Rizos Christos V et al. Atherosclerosis 2018 277308-313
.png)
No hay comentarios:
Publicar un comentario